Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Cancer Prevention Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

NCT02253251
View directory record Official record
Conditions
Cancer
Interventions
KRAS-variant and microRNA binding site mutation testing
Genetic
Lead sponsor
MiraKind
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 25, 2026, 4:54 PM EDT
Active, not recruiting Phase 2 Interventional

Axillary Reverse Mapping

NCT00572481
View directory record Official record
Conditions
Cancer of the Breast
Interventions
Axillary Reverse Mapping
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Phase 3 Interventional Results available

S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo

NCT00775645
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Fatigue, Neuropathy, Neurotoxicity
Interventions
acetyl-L-carnitine hydrochloride, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
295
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 196 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 25, 2026, 4:54 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer

NCT00588029
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2026
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Not applicable Interventional

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

NCT05146297
View directory record Official record
Conditions
Breast Cancer, Liver Cancer, Prostate Cancer
Interventions
Clinical trial match-list, Match-list intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Phase 3 Interventional

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

NCT00049452
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Stamford, Connecticut • Paramus, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 25, 2026, 4:54 PM EDT
Terminated Not applicable Interventional Results available

Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction

NCT01649505
View directory record Official record
Conditions
Breast Cancer, Perioperative/Postoperative Complications
Interventions
fibrin sealant (Beriplast P, TISSEEL VH), breast reconstruction
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Not applicable Interventional

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00003538
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 25, 2026, 4:54 PM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 25, 2026, 4:54 PM EDT
Active, not recruiting Not applicable Interventional

CARE (Chemotherapy Alopecia REduction)

NCT07201389
View directory record Official record
Conditions
Breast Cancer, Breast - Female, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Chemotherapy Induced Alopecia
Interventions
Scalp Cooling by DigniCap
Device
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 25, 2026, 4:54 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention

NCT05524480
View directory record Official record
Conditions
Cancer Prevention
Interventions
Salud en Mis Manos - Dissemination and Implementation Assistance, Salud en Mis Manos- Usual Implementation Practice
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Phase 2 Interventional Results available

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

NCT01194440
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
letrozole, zoledronic acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 25, 2026, 4:54 PM EDT
Recruiting Phase 2 Interventional

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

NCT07459673
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions
Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 25, 2026, 4:54 PM EDT
Not listed Phase 2 Interventional

Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

NCT00651417
View directory record Official record
Conditions
Localized Breast Cancer, Localized Prostate Cancer, Patients Receiving External Beam Radiotherapy
Interventions
Organic Germanium, Placebo
Dietary Supplement
Lead sponsor
Arizona Oncology Services
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 25, 2026, 4:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Effects of Exemestane on Bone Strength

NCT01144468
View directory record Official record
Conditions
Osteoporosis, Breast Cancer
Interventions
Not listed
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older · Female only
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2022
U.S. locations
2
States / cities
Sacramento, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 25, 2026, 4:54 PM EDT
Recruiting No phase listed Observational

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 25, 2026, 4:54 PM EDT
Active, not recruiting Phase 2 Interventional

The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment

NCT05458284
View directory record Official record
Conditions
Breast Cancer, Taxane-Induced Peripheral Neuropathy
Interventions
Real Acupuncture, Sham Acupuncture
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Phase 2 Interventional Results available

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

NCT02177175
View directory record Official record
Conditions
Breast Cancer
Interventions
Carvedilol, placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 25, 2026, 4:54 PM EDT
Not listed No phase listed Observational

Tear Based Sample Collection Breast Cancer Detection

NCT04974567
View directory record Official record
Conditions
Breast Cancer, Tear, Breast Cancer Female
Interventions
Schirmer Strip
Other
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Phase 2 Interventional

Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus

NCT02229136
View directory record Official record
Conditions
Stomatitis, Oral Mucositis, Neoplasm of the Breast, Malignant Tumor of Breast
Interventions
Miracle Mouthwash Plus Hydrocortisone, Prednisolone
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
US, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 25, 2026, 4:54 PM EDT
Terminated Phase 2 Interventional

Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer

NCT04149522
View directory record Official record
Conditions
Breast Cancer, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Radiotherapy Side Effect, Radiation Burn, Radiation Dermatitis, Radiotherapy; Complications
Interventions
Mepitel Film®
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Clairton, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating Tools for Health Promotion and Disease Prevention

NCT00164658
View directory record Official record
Conditions
Coronary Heart Disease, Stroke, Diabetes, Breast Cancer, Ovarian Cancer, Colorectal Cancer
Interventions
Familial risk assessment and personalized prevention messages
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
35 Years to 65 Years
Enrollment
8,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
3
States / cities
Evanston, Illinois • Leawood, Kansas • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 25, 2026, 4:54 PM EDT
Completed Phase 2 Interventional Results available

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT03084536
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions
Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 25, 2026, 4:54 PM EDT